A radomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

American Journal of Psychiatry

Volumn 155, Issue 11, 1998, Pages 1512-1520

  Devanand, D P ^a   Marder, Karen ^b   Michaels, Kristin S ^b   Sackeim, Harold A ^b   Bell, Karen ^b   Sullivan, Maria A ^b   Cooper, Thomas B ^b   Pelton, Gregory H ^b   Mayeux, Richard ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO;

ADULT; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; AGED; AGGRESSION; AMBULATORY CARE; BLOOD; BRIEF PSYCHIATRIC RATING SCALE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DELUSION; DRUG ADMINISTRATION; EXTRAPYRAMIDAL SYNDROME; HALLUCINATION; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RESTLESSNESS; STATISTICS; TREATMENT OUTCOME;

AGED; AGGRESSION; ALZHEIMER DISEASE; AMBULATORY CARE; BASAL GANGLIA DISEASES; BRIEF PSYCHIATRIC RATING SCALE; CROSS-OVER STUDIES; DELUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALLUCINATIONS; HALOPERIDOL; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031596208     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.11.1512     Document Type: Article

References (53)

1. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48:9-15
2. Rubin EH, Morris JC, Berg L: The progression of personality changes in senile dementia of the Alzheimer's type. J Am Geriatr Soc 1987; 35:721-725
3. Devanand DP, Jacobs DM, Tang M, Castillo-Castaneda CD, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y: The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry 1997; 54:257-263
4. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T: Predictors of disease course in patients with probable Alzheimer's disease. Neurology 1987; 37:1649-1653
5. Drevets WC, Rubin EH: Psychotic symptoms and the longitudinal course of dementia of the Alzheimer type. Biol Psychiatry 1989; 25:39-48
6. Rosen J, Zubenko GS: Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 1991; 29:224-232
7. Devanand DP, Brockington CD, Moody BJ, Brown RP, Mayeux R, Endicott J, Sackeim HA: Behavioral syndromes in Alzheimer's disease. Int Psychogeriatr 1992; 4:161-184
8. Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in a nursing home. Gerontology 1989; 3:M77-M84
9. Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL: Troublesome and disruptive behaviors in dementia. J Am Geriatr Soc 1988; 36:784-790
10. Reisberg B, Franssen E, Sclan SG, Kluger A, Ferris SH: Stage-specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci 1989; 54: 95-112
11. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146:577-587
12. Small GW, Jarvik LF: The dementia syndrome. Lancet 1982; 11:1443-1445
13. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982; 248:333-335
14. Haller E, Binder RL, McNeil DE: Violence in geriatric patients with dementia. Bull Am Acad Psychiatry Law 1989; 17:183-188
15. Leibovici A, Tariot PN: Agitation associated with dementia: a systematic approach to treatment. Psychopharmacol Bull 1988; 24:39-42
16. Beardsley RS, Larson DB, Burns BJ, Thompson JW, Kamerow DB: Prescribing of psychotropics in elderly nursing home patients. J Am Geriatr Soc 1989; 37:327-330
17. Avorn J, Dreyer P, Connelly K, Soumerai SB: Use of psychotropic medication and the quality of care in rest homes. N Engl J Med 1989; 320:227-232
18. Rada RT, Kellner R: Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976; 24:105-107
19. Petrie WM, Ban TA, Berney S, Fujimori M, Guy W, Ragheb M, Wilson WH, Schaffer DJ: Loxapine in psychogeriatrics: a placebo and standard controlled clinical investigation. J Clin Psychopharmacol 1982; 2:122-126
20. Barnes R, Veith R, Okimoto J, Raskind M, Gumbrecht G: Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139:1170-1174
21. Schneider LS, Pollock VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563
22. Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993; 19:817-830
23. Devanand D, Sackeim H, Brown R, Mayeux R: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854-857
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
25. Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35:837-844
26. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
27. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 1976; 1:1403
28. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2:1457-1459
29. Tune L, Carr S, Hoag E, Cooper T: Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-1394
30. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976
31. Wocjik JD, Gelenburg AJ, La Brie RA, Mieske M: Prevalence of tardive dyskinesia in an outpatient population. Compr Psychiatry 1980; 21:370-380
32. Simpson GM, Lee JH, Zoubok B, Gardos G: A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171-179
33. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
34. Mayeux R, Stern Y, Rosen J, Leventhal J: Depression, intellectual impairment and Parkinson's disease. Neurology 1981; 31:645-650
35. Stern Y, Sano M, Paulson J, Mayeux R: Modified Mini-Mental State Examination: validity and reliability. Neurology 1987; 37(suppl 1):179-186
36. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797-811
37. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572
38. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
39. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
40. Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52:173-188
41. Finkel SI, Lyons JS, Anderson RL, Sherrell K, Davis J, Cohen-Mansfield J, Schwartz A, Gandy J, Schneider L: A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10:129-136
42. Raskind M, Risse S, Lampe T: Dementia and antipsychotic drugs. J Clin Psychiatry 1987; 48:16-18
43. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK: Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22:911-922
44. McKeith IG, Galasko D, Kosaka M, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra S, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH, for the Consortium on Dementia with Lewy Bodies: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996; 47:1113-1124
45. Jeanblanc W, Davis YB: Risperidone for treating dementia-associated aggression (letter). Am J Psychiatry 1995; 152:1239
46. Chengappa RKN, Baker RW, Kreinbrook SB, Adair D: Clozapine use in female geriatric patients with psychosis. J Geriatr Psychiatry Neurol 1995; 8:12-15
47. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T: Do neuroleptic drugs hasten cognitive decline in dementia? prospective study with necropsy follow-up. Br Med J 1997; 314:266-270
48. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB: Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997; 54:836-840
49. Dysken MW, Johnson SB, Holdon L, Vatassery G, Nygren J, Jelinski M, Kuskowski M, Schut L, McCarten JR, Knopman D, Maletta GJ, Skare S: Haloperidol concentrations in patients with Alzheimer's dementia. Am J Geriatr Psychiatry 1994; 2: 125-133
50. Sakalis G, Curry SH, Mould GP, Lader MH: Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 1972; 13:931-946
51. Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, Lindberg A, Lindstrom L: Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology (Berl) 1987; 91:410-414
52. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou JC, Crowner M, Douyon R: Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49:354-361
53. Van Putten T, Marder SR, Mintz J, Poland R: Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol Bull 1988; 24:172-175